Research
Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
The Brief
- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced heavy drinking days per week in patients with moderate-to-severe alcohol use disorder.
- The result comes from the phase II RECLAIM trial, as reported by MedPage Today from AASLD meeting coverage.
Why it matters
Heavy drinking days are a core outcome in alcohol use disorder, so a significant reduction in a phase II trial signals a possible new drug approach for clinicians and researchers, though it is not yet an approved treatment.
Who’s affected
- clinicians treating alcohol use disorder
- addiction medicine researchers
- people following GLP-1 drug development
- #alcohol use disorder
- #glp-1
- #pemvidutide
- #clinical trial
- #addiction medicine
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM...